Purpose: This study aimed to compare the intraocular pressure (IOP)-lowering effects of timolol (a β-blocker), brinzolamide (a carbonic anhydrase inhibitor), brimonidine (an α2-agonist) and netarsudil (a rho kinase inhibitor) in rabbits.
Methods: The experiments were performed on 52 female New Zealand white rabbits. The IOP was measured in normotensive rabbits and in water loading-induced ocular hypertension model rabbits. Thirty microliters of timolol, brinzolamide, brimonidine, netarsudil or saline was administered topically to the randomly chosen eye. Ocular hypertension was induced by the oral administration of 60 mL/kg of tap water.
Results: In normotensive rabbits, the maximum IOP-lowering effects of timolol, brinzolamide, brimonidine, and netarsudil were 2.9 mmHg (2 h), 5.2 mmHg (1 h), 5.7 mmHg (2 h), and 3.3 mmHg (4 h), respectively. In water loading-induced ocular hypertension model rabbits, the maximum IOP-lowering effects of timolol, brinzolamide, brimonidine, and netarsudil were 3.6, 5.0, 12.2, and 5.0 mmHg, respectively. The IOP-lowering effects of brimonidine and netarsudil were sustained until 90 min after water loading.
Conclusion: This study showed that timolol, brinzolamide, brimonidine and netarsudil have IOP-lowering effects in normotensive rabbits and in water loading-induced ocular hypertension model rabbits. In an ocular hypertension rabbit model, brimonidine and netarsudil, which promote aqueous humor outflow, exhibited stronger IOP-lowering effects than timolol and brinzolamide, which suppress aqueous humor production. These results could provide data for characterizing each medication. These data may aid in the development of new glaucoma medications through the combination of existing medications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/02713683.2025.2472365 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the Effects of Timolol, Brinzolamide, Brimonidine and Netarsudil in a Rabbit Model of Water Loading-Induced Ocular Hypertension.
Curr Eye Res
March 2025
Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd, Tokushima, Japan.
Purpose: This study aimed to compare the intraocular pressure (IOP)-lowering effects of timolol (a β-blocker), brinzolamide (a carbonic anhydrase inhibitor), brimonidine (an α2-agonist) and netarsudil (a rho kinase inhibitor) in rabbits.
Methods: The experiments were performed on 52 female New Zealand white rabbits. The IOP was measured in normotensive rabbits and in water loading-induced ocular hypertension model rabbits.
Difficult decisions, filtration surgery, and the heartbreak of the numerator.
J Cataract Refract Surg
January 2024
Minneapolis, Minnesota.
Article Synopsis
- A 70-year-old man with severe glaucoma had previous surgeries including selective laser trabeculoplasty and minimally invasive glaucoma surgery while also being intolerant to multiple medications.* -
- After consultation with a neuro-ophthalmologist, a trabeculectomy was performed on the left eye, which stabilized its intraocular pressure (IOP) for nearly two years, while the right eye continued to deteriorate.* -
- Visual acuity measurements showed significant impairment in the left eye (20/250) compared to the right eye (20/25), with the right eye's IOP at 20 mm Hg and ongoing treatment with medications.*
Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye.
J Cataract Refract Surg
July 2023
Minneapolis, Minnesota.
A 62-year-old woman with mild myopia presented to her local optometrist for a routine examination and was found to have intraocular pressure (IOP) of 30 mm Hg in both eyes and cupped nerves. She had a family history of glaucoma in her father. She was started on latanoprost in both eyes and was referred for a glaucoma evaluation.
View Article and Find Full Text PDFEffectiveness of Netarsudil versus Brimonidine in Eyes already Being Treated with Glaucoma Medications at a Single Academic Tertiary Care Practice: A Comparative Study.
Curr Ther Res Clin Exp
November 2022
Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Background: Rho kinase inhibitors, such as netarsudil, are a relatively new class of medications recently introduced into the market for the treatment of glaucoma, the leading cause of irreversible blindness in the world. Previous clinical trials have studied netarsudil's efficacy when used as a first- or second-line agent but limited studies have investigated its effectiveness in the real world where it is more commonly used as a third, fourth, or fifth agent in combination with other topical medications. Equally important, prior studies have not compared its effectiveness to its peer medications in these settings.
View Article and Find Full Text PDFExtreme intraocular pressure and steroid-dependent iritis.
J Cataract Refract Surg
January 2023
Minneapolis, Minnesota.
A 50-year-old ophthalmic technician was referred by her retina specialist for urgent consultation due to markedly elevated intraocular pressure (IOP) unresponsive to medical therapy. Her history included chronic polyarticular juvenile rheumatoid arthritis and chronic uveitis requiring ongoing topical steroid therapy. She had a sub-Tenon injection of Kenalog (triamcinolone) 18 months prior to referral.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!